Two separate teal component forms in a grouped arrangement.

Our evidence assessments are specific to a combination, outcome, population, and formulation.

Read our grading method

Semax + Selank

Semax + Selank

Semax + Selank: ingredient studies, complete-combination evidence gaps, dose, route and safety questions in the available research.

Peptide stack
Primary investigators

Recorded source check: 4 October 2026

Review and updates

Overview

This guide covers Semax + Selank as a proposed combination. No primary study record of the complete combination is currently attached to this page, so the material here cannot establish an added benefit, a validated combined regimen, or a reliable rate of adverse events. Ingredient studies remain useful background, but they answer narrower questions about the intervention each paper actually tested. The gap described here concerns this guide’s linked sources and is not a claim that the combination has never been studied elsewhere.

Ingredients

  • SemaxRead the ingredient evidence and its limits.
  • SelankRead the ingredient evidence and its limits.

The combination examined on this page contains Semax + Selank. Each ingredient needs to be identified by its actual molecule and preparation before research can be matched to the combination. The linked ingredient guides provide a route into that evidence, while ingredients without a dedicated guide remain named explicitly. A shared nickname, similar product label, or premixed presentation cannot establish that every ingredient, concentration, and route matches a published intervention.

Why combine them?

The reason to investigate Semax + Selank together must be separated from evidence that the combination improves an outcome. A plausible role for each ingredient can motivate a study, but it does not show whether their effects complement one another, overlap, or introduce additional problems. The sources attached to this guide do not resolve that comparison for the complete stack. A convincing test would compare the proposed combination with the relevant individual ingredients and measure both the intended benefit and adverse events.

Combination benefits

No effectiveness assessment for the complete Semax + Selank combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Safety & interactions

This page does not establish the safety or interaction profile of Semax + Selank taken together. Assessing that question requires the full formulation, route, exposure, concurrent treatments, and adverse-event reporting from relevant combination research. Tolerability observed with an ingredient alone cannot establish the safety of adding the other ingredients, and missing reports cannot be treated as reassurance. Any proposed clinical use also requires an assessment of the individual’s circumstances rather than a conclusion drawn solely from a stack name.

Read the Medical Disclaimer.

Forms & dosing

The sources attached to this guide do not establish a validated dose, ingredient ratio, route, or cycle for the complete Semax + Selank combination. A schedule reported for one ingredient remains part of that study’s intervention and should not be combined with a second paper’s schedule to create a new protocol. Formulation and administration details also need to match before results can be applied. Accordingly, reported study amounts are treated as source information rather than a recommendation for using this stack.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Complete-combination evidence has not yet been assessed for this guide.

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

No study of this exact combination is available in this collection. The studies below concern individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.

IngredientPDF recordSemax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models
IngredientPDF recordSemax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing
IngredientPDF recordThe peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
IngredientPDF recordCorrection of Long-Lasting Negative Effects of Neonatal Isolation in White Rats Using Semax
IngredientPDF recordA Mouse Model of Nigrostriatal Dopaminergic Axonal Degeneration As a Tool for Testing Neuroprotectors
IngredientPDF recordThe Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer’s Disease
IngredientPDF recordACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke
IngredientPDF recordProtective Effects of PGC-1α Activators on Ischemic Stroke in a Rat Model of Photochemically Induced Thrombosis
IngredientPDF recordInsight into Glyproline Peptides’ Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia–Reperfusion
IngredientPDF recordSynthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period
IngredientPDF recordBrain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion
IngredientPDF recordAntistress Action of Melanocortin Derivatives Associated with Correction of Gene Expression Patterns in the Hippocampus of Male Rats Following Acute Stress
IngredientPDF recordGenes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage
IngredientPDF recordDigitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study
IngredientPDF recordStrategy to discover full-length amyloid-beta peptide ligands using high-efficiency microarray technology
IngredientPDF recordPeptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
IngredientPDF recordSelank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
IngredientPDF recordGABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells

FAQs

Do the ingredient studies prove that the complete stack works?
Quick answer:

No effectiveness assessment for the complete Semax + Selank combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Can separate study doses be combined into a stack protocol?
Quick answer:

The sources attached to this guide do not establish a validated dose, ingredient ratio, route, or cycle for the complete Semax + Selank combination. A schedule reported for one ingredient remains part of that study’s intervention and should not be combined with a second paper’s schedule to create a new protocol. Formulation and administration details also need to match before results can be applied. Accordingly, reported study amounts are treated as source information rather than a recommendation for using this stack.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for Semax + Selank.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

0 sources

This page does not yet have an assessed reference supporting a clinical conclusion about the complete topic. Ingredient links and the broader source library can help locate relevant research, but a related paper is not automatically evidence for the intervention named here. Any future citation needs to be matched to its actual population, formulation, comparison, and outcome. The absence of a reference on this page describes the present review and should not be interpreted as a literature-wide absence of research.